Please use this identifier to cite or link to this item:
https://www.um.edu.mt/library/oar/handle/123456789/150270| Title: | Empagliflozin use and outcomes in heart failure with reduced ejection fraction : a comparative study |
| Authors: | Jarboua, Yosef Moore, Alice M. Cassar Maempel, Andrew Camilleri, Liberato Wirth, Francesca |
| Keywords: | Heart failure -- Treatment Sodium-glucose transporter 2 inhibitors Drug monitoring Drugs -- Toxicology Kidneys -- Diseases |
| Issue Date: | 2026 |
| Publisher: | University of Malta. Department of Pharmacy |
| Citation: | Jarboua, Y., Moore, A, M., Cassar Maempel, A., Camilleri, L., & Wirth, F. (2026). Empagliflozin use and outcomes in heart failure with reduced ejection fraction: a comparative study. ESCP annual Symposium, Portugal. |
| Abstract: | Empagliflozin is an established disease-modifying therapy for heart failure with reduced ejection fraction (HFrEF), and has recently become available through the Maltese National Health Service for patients with chronic heart failure. This expanded access is expected to increase empagliflozin use in routine clinical practice, creating a timely opportunity to generate local real-world evidence on its effectiveness and safety. Aim: To assess clinical outcomes and safety associated with empagliflozin use in patients with HFrEF in routine clinical practice. |
| URI: | https://www.um.edu.mt/library/oar/handle/123456789/150270 |
| Appears in Collections: | Scholarly Works - FacM&SPha |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| Empagliflozin_use_and_outcomes_in_heart_failure_with_reduced_ejection_fraction_a_comparative_study(2026).pdf | 314.93 kB | Adobe PDF | View/Open |
Items in OAR@UM are protected by copyright, with all rights reserved, unless otherwise indicated.